Patents by Inventor Michael Rigby
Michael Rigby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250066421Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: October 4, 2024Publication date: February 27, 2025Inventors: Paul Beswick, Liuhong Chen, Gemma Elizabeth Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby, Stephen Blakemore, Tara Gelb, Nicholas Keen
-
Publication number: 20250051392Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: August 7, 2024Publication date: February 13, 2025Applicant: BicycleTx LimitedInventors: Stephen J. Blakemore, Tara Gelb, Nicholas Keen, Michael Rigby
-
Publication number: 20250002536Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: August 13, 2024Publication date: January 2, 2025Applicant: BicycleTx LimitedInventors: Stephen J. Blakemore, Tara Gelb, Nicholas Keen, Michael Rigby
-
Publication number: 20240400616Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: January 30, 2024Publication date: December 5, 2024Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
-
Publication number: 20240391959Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: ApplicationFiled: March 19, 2024Publication date: November 28, 2024Inventors: Ellen GOWANS, Gemma Elizabeth MUDD, Michael RIGBY, Punit SETH, Michael SKYNNER, Steven STANWAY, Liudvikas URBONAS, Katerine VAN RIETSCHOTEN
-
Publication number: 20240382605Abstract: Provided herein are oligomeric compounds comprising a bicycle ligand and a modified oligonucleotide. This compound may comprise a bicycle ligand as the cell-targeting moiety, and may also comprise a conjugate linker to connect the bicycle ligand and modified oligonucleotide. This compound may be used in conjunction with a pharmaceutically acceptable salt.Type: ApplicationFiled: September 29, 2022Publication date: November 21, 2024Applicants: Ionis Pharmaceuticals, Inc., BicycleTx LimitedInventors: Punit P. Seth, Michael Oestergaard, Michele Carrer, Michael Tanowitz, Michael Rigby, Michael Skynner, Steven Stanway, Liudvikas Urbonas, Katerine Van Rietschoten
-
Publication number: 20240192568Abstract: In some implementations, a controller may apply a set of phase dithers to a first inner Mach-Zehnder (MZ) interferometer and a second inner MZ interferometer, the first inner MZ interferometer and the second inner MZ interferometer being included in an outer MZ interferometer, the set of phase dithers including a first in-phase dither state and a second in-phase dither state and including a first anti-phase dither state and a second anti-phase dither state. The controller may determine an initial error term based at least in part on the set of phase dithers. The controller may adjust, based on the initial error term, the outer MZ interferometer to a target phase associated with a target error term, wherein respective branches of at least one of the first MZ interferometer or the second MZ interferometer are adjusted differentially.Type: ApplicationFiled: March 7, 2023Publication date: June 13, 2024Inventors: Brian GARRETT, Amyas HOLROYD, Chalani ABEYWARDENA, Michael RIGBY-JONES
-
Publication number: 20240173422Abstract: The present invention relates to drug conjugates comprising at least two polypeptides which are each covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also relates to pharmaceutical compositions comprising said drug conjugates and to the use of said drug conjugates in preventing, suppressing or treating diseases, such as those which may be alleviated by cell death, in particular diseases characterised by defective cell types, proliferative disorders such as cancer and autoimmune disorders such as rheumatoid arthritis.Type: ApplicationFiled: October 15, 2020Publication date: May 30, 2024Inventors: Paul Beswick, Gemma MUDD, Michael RIGBY
-
Patent number: 11970555Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: GrantFiled: November 12, 2021Date of Patent: April 30, 2024Assignee: BicycleTx LimitedInventors: Ellen Gowans, Gemma Elizabeth Mudd, Michael Rigby, Punit Seth, Michael Skynner, Steven Stanway, Liudvikas Urbonas, Katerine Van Rietschoten
-
Patent number: 11912792Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: August 17, 2022Date of Patent: February 27, 2024Assignee: BicycleTx LimitedInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20230287047Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: August 17, 2022Publication date: September 14, 2023Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
-
Publication number: 20230233698Abstract: The present invention relates to a Bicycle toxin conjugate BT5528, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.Type: ApplicationFiled: June 11, 2021Publication date: July 27, 2023Inventors: Gavin BENNETT, Stephen BLAKEMORE, Carly CAMPBELL, Michael RIGBY
-
Publication number: 20230181749Abstract: The present invention relates to a Bicycle toxin conjugate BT8009, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof. In one embodiment, the pharmaceutical composition comprises BT8009, histidine, sucrose and Polysorbate 20. In another embodiment, the pharmaceutical composition is for use in treating an advanced solid tumor malignancy associated with Nectin-4-expression in a patient, preferably in combination with Nivolumab.Type: ApplicationFiled: May 20, 2021Publication date: June 15, 2023Inventors: Amy Katherine DICKSON, Darren LIMB, Lisa MAHNKE, Michael RIGBY, Terrence Allen WEST, David WITTY
-
Patent number: 11453702Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: September 30, 2021Date of Patent: September 27, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20220194988Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: ApplicationFiled: November 12, 2021Publication date: June 23, 2022Inventors: Ellen GOWANS, Gemma Elizabeth MUDD, Michael RIGBY, Punit SETH, Michael SKYNNER, Steven STANWAY, Liudvikas URBONAS, Katerine VAN RIETSCHOTEN
-
Publication number: 20220089643Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: September 30, 2021Publication date: March 24, 2022Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
-
Patent number: 11180531Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: June 20, 2019Date of Patent: November 23, 2021Assignee: BicycleTx LimitedInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20210269480Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4.The invention also includes drug conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: June 21, 2019Publication date: September 2, 2021Inventors: Paul BESWICK, Liuhong CHEN, Gemma Elizabeth MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
-
Patent number: 10537933Abstract: A container closure includes a generally planar body having a product side and a customer side. The body includes a container opening. The container opening includes a shifted material line.Type: GrantFiled: September 6, 2017Date of Patent: January 21, 2020Assignee: Stolle Machinery Company, LLCInventors: Aaron Emmanuel Carstens, Patrick Kevin McCarty, Justin Michael Rigby
-
Publication number: 20190389906Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: June 20, 2019Publication date: December 26, 2019Inventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby